Baseline 25-hydroxyvitamin D and progression-free survival in de novo metastatic hormone-sensitive prostate cancer: prognostic model development and external validation
The Oncologist · 2026
DOI: 10.1093/oncolo/oyag396 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift The Oncologist, 2026. Verfasst von Galip Can Uyar und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Etlik City Hospital, Ankara, 06170, Turkey. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Vitamin D. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Prognostic biomarkers for risk stratification remain limited in de novo metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen receptor pathway inhibitors (ARPIs). We evaluated baseline serum 25-hydroxyvitamin D [25(OH)D] and developed and externally validated a progression-free survival (PFS) model.
Methods
This multicenter retrospective study included 273 patients initiating ARPI-based therapy between January 2021 and April 2026. Etlik City Hospital formed the training cohort (n = 192; 85 PFS events), and Gazi University and Kütahya City Hospital formed the external validation cohort (n = 81; 27 PFS events). LASSO-penalized Cox regression retained age, ISUP grade group, CHAARTED disease volume, log-transformed PSA, and hemoglobin. Model B added continuous 25(OH)D. Internal validation used 1000 bootstrap resamples. Performance was assessed by the Harrell C-index, time-dependent AUC, and calibration at 1 and 2 years. PFS was the primary endpoint; overall survival analyses were exploratory. The study was not prospectively registered.
Results
Higher baseline 25(OH)D was associated with longer PFS in Model B (HR per 10-ng/mL increase, 0.64; 95% CI, 0.49-0.83; P < .001). Adding 25(OH)D improved model fit (likelihood-ratio χ² = 12.71; P < .001) and increased apparent C-index from 0.712 to 0.740. In external validation, C-indices were 0.71 (95% CI, 0.64-0.78) and 0.76 (95% CI, 0.69-0.83), respectively (Δ = 0.05; 95% CI, 0.01-0.10).
Conclusions
Baseline 25(OH)D added modest prognostic information beyond clinical factors, with supportive external validation. These findings do not establish treatment-predictive utility or benefit from vitamin D supplementation. Prospective validation is needed before clinical implementation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Etlik City Hospital, Ankara, 06170, Turkey.
- Department of Medical Oncology, Faculty of Medicine, Gazi University, Ankara, 06500, Turkey.
- Department of Medical Oncology, Kütahya City Hospital, Kütahya, 43100, Turkey.
ORCID-Profile: Galip Can Uyar, Kadriye Başkurt, Orhun Akdoğan, Enes Yeşilbaş, Mustafa Ersoy, Tuba Uğur Tuzcu, Kadriye Bir Yücel, Mustafa Altınbaş, Ömür Berna Çakmak Öksüzoğlu, Gökşen İnanç İmamoğlu, Osman Sütcüoğlu
Zitieren
APA
Uyar, G. C., Başkurt, K., Akdoğan, O., Yeşilbaş, E., Ersoy, M., Uğur Tuzcu, T., Bir Yücel, K., Altınbaş, M., Çakmak Öksüzoğlu, Ö. B., İmamoğlu, G. İ., & Sütcüoğlu, O. (2026). Baseline 25-hydroxyvitamin D and progression-free survival in de novo metastatic hormone-sensitive prostate cancer: prognostic model development and external validation. The Oncologist. https://doi.org/10.1093/oncolo/oyag396
Vancouver
Uyar GC, Başkurt K, Akdoğan O, Yeşilbaş E, Ersoy M, Uğur Tuzcu T, et al. Baseline 25-hydroxyvitamin D and progression-free survival in de novo metastatic hormone-sensitive prostate cancer: prognostic model development and external validation. The Oncologist. 2026. doi:10.1093/oncolo/oyag396
BibTeX
@article{Uyar2026,
author = {Uyar, Galip Can and Başkurt, Kadriye and Akdoğan, Orhun and Yeşilbaş, Enes and Ersoy, Mustafa and Uğur Tuzcu, Tuba and Bir Yücel, Kadriye and Altınbaş, Mustafa and Çakmak Öksüzoğlu, Ömür Berna and İmamoğlu, Gökşen İnanç and Sütcüoğlu, Osman},
title = {Baseline 25-hydroxyvitamin D and progression-free survival in de novo metastatic hormone-sensitive prostate cancer: prognostic model development and external validation},
journal = {The Oncologist},
year = {2026},
doi = {10.1093/oncolo/oyag396}
}
EUVIMED